Related Experiment Video
Updated: Sep 7, 2026
An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices
Published on: February 5, 2015
Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis
Scott S Zamvil1, Lawrence Steinman
1Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA. zamvil@ucsf.neuroimmunol.org
Abstract:
Multiple sclerosis (MS) is an autoimmune central nervous system (CNS) demyelinating disease that causes relapsing and chronic neurologic impairment. Recent observations have altered certain traditional concepts regarding MS pathogenesis. A greater diversity of cell types and molecules involved in MS is now evident. While remyelination can occur during the early inflammatory phase when damage may be reversible, it is impaired in the later stages, which involve axonal death. These observations have important therapeutic implications.
Insights
Multiple sclerosis involves central nervous system inflammation and demyelination, impacting neurological function. New insights reveal diverse cellular players and highlight that early remyelination is possible, but later stages with axonal loss impair repair, suggesting new therapeutic avenues.
Area of Science:
- Neuroimmunology
- Central Nervous System (CNS) Diseases
Background:
- Multiple sclerosis (MS) is an autoimmune disorder affecting the CNS.
- It leads to chronic and relapsing neurological impairment due to demyelination.
- Traditional views on MS pathogenesis are evolving with new research.
Purpose of the Study:
- To discuss the updated understanding of Multiple Sclerosis pathogenesis.
- To highlight the dynamic nature of remyelination and axonal damage in MS.
- To underscore the therapeutic implications of these recent observations.
Main Methods:
- Review of recent scientific observations and literature.
- Analysis of cellular and molecular mechanisms in MS.
- Correlation of disease stages with repair and damage processes.
Main Results:
- MS pathogenesis involves a wider array of cells and molecules than previously known.
- Remyelination is feasible in early inflammatory stages but hindered in later chronic phases.
- Axonal death becomes prominent in later MS stages, limiting regenerative potential.
Conclusions:
- Current understanding of MS pathogenesis requires revision based on new data.
- The timing of therapeutic interventions is critical, targeting early reversible damage.
- Impaired remyelination in chronic MS necessitates novel therapeutic strategies to prevent axonal loss.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:19Multiple Sclerosis l: Introduction